GLUT4 as A Protein Target for T2DM Therapy with Natural Compounds

نویسندگان

چکیده

WHO reported 1.9 million death cases of diabetes patients in 2019. Diabetes is caused by damage the pancreas which resulted a lack insulin or resistance. Medication for T2DM mainly focuses on lowering blood glucose and treating affected organs. Current medications are still lacking, thus research needed finding novel to accommodate T2DM. This paper aims present current potential plant extract increasing GLUT4 translocation conditions. resistance state affecting important uptake. Some shows that proved be helping levels.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

P14: Mitochondria as a Target for Drug Therapy in Epilepsy

لطفاً به چکیده انگلیسی مراجعه شود.

متن کامل

Protein phosphatase 2A as a potential target for anticancer therapy.

The kinase oncogenes are well-characterized drivers of cancer development, and several targeted therapies focused on both specific and selectively nonselective kinase inhibitors have now been approved for clinical use. In contrast, much less is known about the role of protein phosphatases, although modulation of their activities might form the foundation for an effective anti-cancer approach. T...

متن کامل

Natural Phyto-Bioactive Compounds for the Treatment of Type 2 Diabetes: Inflammation as a Target

Diabetes is a metabolic, endocrine disorder which is characterized by hyperglycemia and glucose intolerance due to insulin resistance. Extensive research has confirmed that inflammation is closely involved in the pathogenesis of diabetes and its complications. Patients with diabetes display typical features of an inflammatory process characterized by the presence of cytokines, immune cell infil...

متن کامل

One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke

Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke treatment, but its clinical use is limited due to the narrow therapeutic time window and severe adverse effects, including hemorrhagic transformation (HT) and neurotoxicity. One of the potential resolutions is to use adjunct therapies to reduce the side effects and extend t-PA's therapeutic time...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Biology, Medicine & Natural Product Chemistry

سال: 2023

ISSN: ['2089-6514', '2540-9328']

DOI: https://doi.org/10.14421/biomedich.2023.121.289-293